期刊
CELL REPORTS
卷 31, 期 6, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.celrep.2020.107640
关键词
-
类别
资金
- MRC HIU [MC_UU_00008, MC_UU_12009]
- Oxford Single Cell Biology Consortium (OSCBC)
- John Fell Fund [123/737]
- WIMM Strategic Alliance [G0902418, MC_UU_12025]
- UK Medical Research Council (MRC core funding of the MRC Human Immunology Unit)
- Wellcome Trust [100954]
- Swedish Cancer Society
- Swedish Research Council
- C1 KU Leuven Research Council [C14/18/104]
- Wellcome Trust Infection, Immunology & Translational Medicine doctoral programme [105400/Z/14/Z]
- National Institute for Health Research Oxford Biomedical Research Centre
- Wellcome Trust [105400/Z/14/Z] Funding Source: Wellcome Trust
- MRC [G0902418] Funding Source: UKRI
The anti-leukemia agent forodesine causes cytotoxic overload of intracellular deoxyguanosine triphosphate (dGTP) but is efficacious only in a subset of patients. We report that SAMHD1, a phosphohydrolase degrading deoxyribonucleoside triphosphate (dNTP), protects cells against the effects of dNTP imbalances. SAMHD1 - deficient cells induce intrinsic apoptosis upon provision of deoxyribonucleosides, particularly deoxyguanosine (dG). Moreover, dG and forodesine act synergistically to kill cells lacking SAMHD1 Using mass cytometry, we find that these compounds kill SAMHD1-deficient malignant cells in patients with chronic lymphocytic leukemia (CLL). Normal cells and CLL cells from patients without SAMHD1 mutation are unaffected. We therefore propose to use forodesine as a precision medicine for leukemia, stratifying patients by SAMHD1 genotype or expression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据